Longeveron

LGVN · NASDAQ

$1.50+$0.11 (+7.91%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.39

Latest news

Press releaseSep 30, 4:05 PM ETGlobe Newswire
Longeveron to Participate in Three Longevity/Aging Investment Conferences
NewsSep 17, 1:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsSep 17, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsSep 17, 1:59 AM ETTanya Rawat
Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why
Press releaseSep 16, 5:27 PM ETGlobe Newswire
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
NewsAug 25, 8:28 AM ETRishabh Mishra
Stock Market Today: Dow Jones, S&P 500, Nasdaq 1000 Futures Advance as Scott Bessent Expands Sanctions on Iran—NTS, GRRR, REAX, ZM, LGVN in Focus (UPDATED)
NewsAug 25, 4:02 AM ETAvi Kapoor
Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday
NewsAug 24, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseAug 24, 4:05 PM ETGlobe Newswire
Longeveron Announces 1-for-10 Reverse Stock Split
Press releaseAug 19, 4:05 PM ETGlobe Newswire
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
NewsAug 18, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 12, 4:05 PM ETGlobe Newswire
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Press releaseAug 11, 9:05 AM ETGlobe Newswire
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Press releaseJul 23, 9:15 AM ETGlobe Newswire
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Press releaseJul 13, 7:05 AM ETGlobe Newswire
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
Press releaseJul 6, 4:05 PM ETGlobe Newswire
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Press releaseJun 18, 9:20 AM ETGlobe Newswire
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
NewsMay 20, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMay 13, 5:09 PM ET
Longeveron Q1 2026 Earnings Call: Complete Transcript
Press releaseMay 13, 4:05 PM ETGlobe Newswire
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
NewsMay 11, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseApr 23, 6:15 AM ETGlobe Newswire
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Press releaseApr 10, 9:55 AM ETPRNewswire
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Press releaseMar 18, 11:30 AM ETGlobe Newswire
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
NewsMar 18, 11:06 AM ET
Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation
Press releaseMar 18, 10:00 AM ETPRNewswire
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
NewsMar 17, 5:12 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsMar 11, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 10, 3:58 PM ETHenry Khederian
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal
NewsMar 10, 11:09 AM ET
Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation
Press releaseMar 3, 10:02 AM ETPRNewswire
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
NewsFeb 26, 11:05 AM ET
Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation
NewsNov 4, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsAug 5, 8:08 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsAug 4, 5:07 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsJul 8, 12:14 PM ET
Watching Longeveron; Zacks Small-Cap Reiterates $9.55 Price Valuation, Originally Stated On June 24, 2025
NewsJun 24, 11:07 AM ET
Watching Longeveron; Zacks Small-Cap Research Gives Stock $9.55 Price Valuation
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
NewsNov 13, 10:00 AM ET
Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation
NewsNov 4, 3:01 PM ET
Peeling Back The Layers: Exploring Longeveron Through Analyst Insights
NewsOct 28, 6:32 AM ETAvi Kapoor
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
NewsAug 27, 11:00 AM ET
Beyond The Numbers: 4 Analysts Discuss Longeveron Stock
NewsAug 1, 6:55 PM ETChris Katje
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
NewsJul 29, 1:19 PM ETAvi Kapoor
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Longeveron to Participate in Three Longevity/Aging Investment Conferences

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Stock Market Today: Dow Jones, S&P 500, Nasdaq 1000 Futures Advance as Scott Bessent Expands Sanctions on Iran—NTS, GRRR, REAX, ZM, LGVN in Focus (UPDATED)

Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday

12 Health Care Stocks Moving In Monday's After-Market Session

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

12 Health Care Stocks Moving In Tuesday's After-Market Session

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Longeveron® Appoints Marie Washburn as Chief Financial Officer

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)

12 Health Care Stocks Moving In Wednesday's After-Market Session

Longeveron Q1 2026 Earnings Call: Complete Transcript

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Earnings Scheduled For May 13, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed

Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Watching Longeveron; Zacks Small-Cap Reiterates $9.55 Price Valuation, Originally Stated On June 24, 2025

Watching Longeveron; Zacks Small-Cap Research Gives Stock $9.55 Price Valuation

Earnings Scheduled For May 8, 2025

Watching Longeveron; Zacks Small-Cap Research Sets $9.50 Price Valuation

Peeling Back The Layers: Exploring Longeveron Through Analyst Insights

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Beyond The Numbers: 4 Analysts Discuss Longeveron Stock

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session